How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 64.4 | 64.4 | 64.4 | 65.0 | 65.0 | 65.0 | +0.6 |
| Healthcare | 29.3 | 29.3 | 29.3 | 27.5 | 27.5 | 27.5 | -1.8 |
| Chemicals | 5.2 | 5.2 | 5.2 | 6.2 | 6.2 | 6.2 | +1.0 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 14.88% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| DIVISLAB | Pharma | 8.26% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| TORNTPHARM | Pharma | 6.16% | 7 | 8 | 5 | 4 | 1 | — | +7.0% |
| MAXHEALTH | Healthcare | 5.15% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| ACUTAAS | Chemicals | 4.32% | 5 | 10 | 3 | 8 | 2 | — | -8.5% |
| CIPLA | Pharma | 4.32% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| PARKHOSPS | Healthcare | 3.86% | 5 | 9 | 9 | 5 | 3 | — | -3.1% |
| FORTIS | Healthcare | 3.46% | 4 | 8 | 5 | 5 | 6 | — | -12.4% |
| MANKIND | Pharma | 3.26% | 4 | 8 | 9 | 3 | 5 | — | -6.1% |
| SAILIFE | Healthcare | 3.08% | 9 | 10 | 5 | 9 | 1 | Leader | +27.8% |
| YATHARTH | Healthcare | 2.99% | 8 | 9 | 6 | 3 | 3 | — | +17.3% |
| KIMS | Healthcare | 2.95% | 4 | 3 | 6 | 10 | 2 | — | -9.0% |
| GLAND | Pharma | 2.75% | 10 | 7 | 5 | 4 | 4 | Leader | +27.9% |
| LAURUSLABS | Pharma | 2.66% | 9 | 9 | 3 | 3 | 1 | — | +29.2% |
| APOLLOHOSP | Healthcare | 2.63% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| ANTHEM | Pharma | 2.37% | 10 | 10 | 6 | 3 | 1 | Leader | +16.3% |
| AJANTPHARM | Pharma | 2.29% | 8 | 10 | 1 | 3 | 3 | — | +13.9% |
| MARKSANS | Pharma | 2.27% | 10 | 6 | 7 | 3 | 6 | Leader | +37.5% |
| RUBICON | Pharma | 2.19% | 7 | 8 | 5 | 4 | 1 | — | +43.6% |
| ORCHPHARMA | Pharma | 1.88% | 7 | 1 | 4 | 10 | 2 | — | +8.0% |
| EMCURE | Pharma | 1.87% | 10 | 10 | 9 | 10 | 4 | Leader | +7.6% |
| CORONA | Pharma | 1.85% | 5 | 9 | 7 | 2 | 1 | — | +14.6% |
| JUBLINGREA | Chemicals | 1.83% | 5 | 4 | 5 | 3 | 5 | — | +4.8% |
| AUROPHARMA | Pharma | 1.62% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| RAINBOW | Healthcare | 1.56% | 10 | 7 | 4 | 3 | 4 | — | +5.0% |
| LUPIN | Pharma | 1.42% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| JUBLPHARMA | Pharma | 1.37% | 3 | 1 | 3 | 3 | 7 | — | -5.2% |
| METROPOLIS | Pharma | 1.28% | 8 | 9 | 6 | 7 | 1 | — | +4.7% |
| ZYDUSLIFE | Pharma | 1.24% | 9 | 10 | 10 | 2 | 8 | — | +1.9% |
| LALPATHLAB | Healthcare | 1.23% | 7 | 8 | 7 | 5 | 3 | — | +18.6% |
| INNOVACAP | Pharma | 1.10% | 10 | 8 | 6 | 2 | 2 | — | +29.4% |
Performance · 2.7y
Over the last 2.7 years ₹100 in the fund grew to ₹171 (+71%), vs ₹121 for Nifty 500 (+21%) and ₹111 for Nifty 50 (+11%). Its relative-strength line ended at 154 vs Nifty 50 and 142 vs Nifty 500 — above 100, sustained outperformance.